Evidence map›Paper›PMID 31466813›Full record

ArticleUrologic oncology2019

Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.

Jiahua Pan, Chenfei Chi, Hongyang Qian, Yinjie Zhu, Xiaoguang Shao, Jianjun Sha, Fan Xu, Yanqing Wang, Robert J Karnes, Baijun Dong and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Urologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Head-to-head comparisons of [European journal of nuclear medicine and molecular imaging · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jiahua PanDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Chenfei ChiDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Hongyang QianDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Yinjie ZhuDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Xiaoguang ShaoDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Jianjun ShaDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Fan XuDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Yanqing WangDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Robert J KarnesDepartment of Urology, Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN.
Baijun DongDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Wei XueDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Electronic address: uroxuewei@163.com.
Renji Hospital · CNShanghai Jiao Tong University · CNMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDocetaxel has been shown to be an effective chemotherapy agent when combined with androgen deprivation therapy for hormone sensitive metastatic prostate cancer (CaP). Since very high risk CaP has a high rate of occult metastatic disease and early recurrence, we hypothesize that patients with very high risk locally advanced CaP may benefit from docetaxel-based neoadjuvant chemohormonal therapy (NCHT). Thus, we conducted a retrospective study to identify the outcome of these patients treated with NCHT followed by radical prostatectomy (RP). PATIENTS AND

methodsWe retrospectively analyzed data from 177 consecutive patients who had very high risk locally advanced CaP between March 2014 and July 2017. Patients received 3 different therapies: (i) 60 men in NCHT group, (ii) 73 men in neoadjuvant hormonal therapy (NHT) group, and (iii) 44 men received immediate RP without neoadjuvant therapy (No-NT group). Surgical outcomes were analyzed and survival differences were compared by the Kaplan-Meier method.

resultsThe NCHT group had statistically significant higher preoperative Prostate-Specific Antigen (PSA) (P < 0.002), higher Gleason score (P < 0.002), and more advanced clinical stage (P < 0.001) than other groups. After RP, 81% (42/52) of patients in NCHT group, 73% (51/70) of patients in NHT group, and 48% (21/44) of patients in No-NT group achieved an undetectable PSA (P < 0.001). A total of 14% (6/42) patients achieving a postoperative undetectable PSA experienced biochemical recurrence in the NCHT group, with median biochemical progression-free survival (bPFS) time of 19 months; 47% (24/51) experienced biochemical recurrence in the NHT group, with median bPFS time of 13 months; 81% (17/21) experienced biochemical recurrence in the No-NT group, with median bPFS time of 9 months (P < 0.001). The median follow-up time of 3 groups was 12.5 months in the NCHT group, 18.3 months in the NHT group, and 22.8 months in the No-NT group (P = 0.01).

conclusionDespite having poorer prognostic factors, the NCHT group had better bPFS time after surgery compared to NHT and No-NT groups. Randomized controlled investigations are needed to validate these results and further follow-up is required for survival endpoints.

Indexed as

ProstatectomyAgedAndrogen AntagonistsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionDocetaxelFollow-Up StudiesHumansKallikreinsKaplan-Meier EstimateLymph Node ExcisionMaleMiddle AgedNeoadjuvant TherapyNeoplasm GradingAndrogen AntagonistsAntineoplastic Agents, HormonalDocetaxelKallikreinsKLK3 protein, humanProstate-Specific AntigenBiochemical recurrenceExtended pelvic lymph node dissectionNeoadjuvant chemohormonal therapyRadical prostatectomy

Identifiers

PMID31466813
OpenAlexW2971350849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.